PuraPharm Corp Ltd
HKEX:1498
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
PuraPharm Corp Ltd
EPS (Diluted)
PuraPharm Corp Ltd
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PuraPharm Corp Ltd
HKEX:1498
|
EPS (Diluted)
HK$0
|
CAGR 3-Years
36%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
EPS (Diluted)
$0
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Grand Pharmaceutical Group Ltd
HKEX:512
|
EPS (Diluted)
HK$0
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
15%
|
|
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
EPS (Diluted)
¥0
|
CAGR 3-Years
0%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
0%
|
|
|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
EPS (Diluted)
HK$0
|
CAGR 3-Years
5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
EPS (Diluted)
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
PuraPharm Corp Ltd
Glance View
PuraPharm Corp. Ltd. is an investment holding company, which engages in the research and development, production and sale of concentrated Chinese medicine granule (CCMG) products and Chinese healthcare products, as well as rendering of Chinese medical diagnostic services. The firm operates through five business segments. The China CCMG segment is mainly engaged in the production and sales of CCMG products in China. The Hong Kong CCMG segment is mainly engaged in the sales of CCMG products, excluding the sales through self-operated clinics in Hong Kong. The Chinese Healthcare Products segment is mainly engaged in the production and sales of healthcare products in Hong Kong and China. The Clinics segment is mainly engaged in the provision of Chinese medical diagnostic services and sales of CCMG products through self-operated clinics. The Plantation segment is mainly engaged in the plantation and trading of raw Chinese herbs, and the manufacture and sale of traditional Chinese medicine (TCM) decoction pieces.
See Also
What is PuraPharm Corp Ltd's EPS (Diluted)?
EPS (Diluted)
-0.1
HKD
Based on the financial report for Dec 31, 2025, PuraPharm Corp Ltd's EPS (Diluted) amounts to -0.1 HKD.
What is PuraPharm Corp Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 3Y
36%
Over the last year, the EPS (Diluted) growth was 11%. The average annual EPS (Diluted) growth rates for PuraPharm Corp Ltd have been 36% over the past three years .
